Charles Schwab’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $8.02M | Buy |
574,021
+8,058
| +1% | +$113K | ﹤0.01% | 2119 |
|
|
2025
Q1 | $7.63M | Sell |
565,963
-9,107
| -2% | -$123K | ﹤0.01% | 2084 |
|
|
2024
Q4 | $11M | Buy |
575,070
+58,857
| +11% | +$1.13M | ﹤0.01% | 1968 |
|
|
2024
Q3 | $11.7M | Buy |
516,213
+32,292
| +7% | +$735K | ﹤0.01% | 1952 |
|
|
2024
Q2 | $6.3M | Buy |
483,921
+59,836
| +14% | +$778K | ﹤0.01% | 2252 |
|
|
2024
Q1 | $7.43M | Buy |
424,085
+52,774
| +14% | +$924K | ﹤0.01% | 2135 |
|
|
2023
Q4 | $8.09M | Buy |
371,311
+58,094
| +19% | +$1.27M | ﹤0.01% | 2099 |
|
|
2023
Q3 | $4.8M | Buy |
313,217
+197,430
| +171% | +$3.03M | ﹤0.01% | 2279 |
|
|
2023
Q2 | $2.75M | Buy |
115,787
+11,717
| +11% | +$279K | ﹤0.01% | 2454 |
|
|
2023
Q1 | $2.65M | Buy |
104,070
+1,830
| +2% | +$46.6K | ﹤0.01% | 2448 |
|
|
2022
Q4 | $2.99M | Buy |
102,240
+28,691
| +39% | +$838K | ﹤0.01% | 2438 |
|
|
2022
Q3 | $1.51M | Buy |
73,549
+5,303
| +8% | +$109K | ﹤0.01% | 2660 |
|
|
2022
Q2 | $790K | Buy |
+68,246
| New | +$790K | ﹤0.01% | 2884 |
|
|
2019
Q2 | – | Sell |
-3,200
| Closed | -$134K | – | 3266 |
|
|
2019
Q1 | $134K | Hold |
3,200
| – | – | ﹤0.01% | 3069 |
|
|
2018
Q4 | $146K | Hold |
3,200
| – | – | ﹤0.01% | 3056 |
|
|
2018
Q3 | $268K | Hold |
3,200
| – | – | ﹤0.01% | 3026 |
|
|
2018
Q2 | $308K | Buy |
3,200
+873
| +38% | +$84K | ﹤0.01% | 2952 |
|
|
2018
Q1 | $245K | Buy |
2,327
+907
| +64% | +$95.5K | ﹤0.01% | 2940 |
|
|
2017
Q4 | $223K | Hold |
1,420
| – | – | ﹤0.01% | 2961 |
|
|
2017
Q3 | $195K | Hold |
1,420
| – | – | ﹤0.01% | 3016 |
|
|
2017
Q2 | $276K | Buy |
+1,420
| New | +$276K | ﹤0.01% | 2899 |
|